Alphavirus replicon DNA expressing HIV antigens is an excellent prime for boosting with recombinant modified vaccinia Ankara (MVA) or with HIV gp140 protein antigen.

Abstract

Vaccination with DNA is an attractive strategy for induction of pathogen-specific T cells and antibodies. Studies in humans have shown that DNA vaccines are safe, but their immunogenicity needs further improvement. As a step towards this goal, we have previously demonstrated that immunogenicity is increased with the use of an alphavirus DNA-launched replicon (DREP) vector compared to conventional DNA vaccines. In this study, we investigated the effect of varying the dose and number of administrations of DREP when given as a prime prior to a heterologous boost with poxvirus vector (MVA) and/or HIV gp140 protein formulated in glucopyranosyl lipid A (GLA-AF) adjuvant. The DREP and MVA vaccine constructs encoded Env and a Gag-Pol-Nef fusion protein from HIV clade C. One to three administrations of 0.2 μg DREP induced lower HIV-specific T cell and IgG responses than the equivalent number of immunizations with 10 μg DREP. However, the two doses were equally efficient as a priming component in a heterologous prime-boost regimen. The magnitude of immune responses depended on the number of priming immunizations rather than the dose. A single low dose of DREP prior to a heterologous boost resulted in greatly increased immune responses compared to MVA or protein antigen alone, demonstrating that a mere 0.2 μg DREP was sufficient for priming immune responses. Following a DREP prime, T cell responses were expanded greatly by an MVA boost, and IgG responses were also expanded when boosted with protein antigen. When MVA and protein were administered simultaneously following multiple DREP primes, responses were slightly compromised compared to administering them sequentially. In conclusion, we have demonstrated efficient priming of HIV-specific T cell and IgG responses with a low dose of DREP, and shown that the priming effect depends on number of primes administered rather than dose.

• Authors: Maria L Knudsen, Karl Ljungberg, Roger Tatoud, Jonathan Weber, Mariano Esteban, Peter Liljeström
• Journal: PloS one (PLoS One) Vol. 10 Issue 2 Pg. e0117042 ( 2015) ISSN: 1932-6203 [Electronic] United States
• PMID: 25643354 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antibodies, Viral
• DNA, Recombinant
• DNA, Viral
• HIV Antigens
• Immunoglobulin G
• Lipid A
• Vaccines, DNA
• env Gene Products, Human Immunodeficiency Virus
• gp140 envelope protein, Human immunodeficiency virus 1

Topics

• Alphavirus (genetics)
• Animals
• Antibodies, Viral (immunology)
• Chemistry, Pharmaceutical
• DNA, Recombinant (genetics)
• DNA, Viral (genetics)
• Female
• Gene Expression
• Genetic Vectors (genetics)
• HIV Antigens (genetics, immunology)
• HIV-1 (immunology)
• Immunization, Secondary
• Immunoglobulin G (immunology)
• Lipid A (chemistry)
• Mice
• Mice, Inbred BALB C
• Replicon (genetics)
• T-Lymphocytes (immunology)
• Vaccines, DNA (genetics, immunology)
• Vaccinia virus (genetics)
• env Gene Products, Human Immunodeficiency Virus (chemistry, immunology)